US-based contract research organisation (CRO) ResearchPoint Global (RPG) has raised its profile in Western Europe by forming a partnership with Pivotal S.L., a full-service Spanish CRO and medical/pharmaceutical consultancy.

A leading CRO in Spain, Pivotal notably brings to the alliance an organisation arranged by therapeutic area, a medical and pharmaceutical hub with seven medical staff, and a strong data management/biostatistics (DMBS) division based on the fully integrated Oracle Health Sciences Suite, RPG said.

While serving the whole range of therapeutic areas, the Spanish company has “considerable experience” in onco-haematology, cardiovascular disease, anti-infectives, immunology and central nervous system disorders, its US partner added.

“As RPG continues to strategically expand its global footprint, Pivotal allows us to better serve our current and prospective clients, especially in oncology, with their extensive expertise that is second to none in Europe,” commented John Farinacci, chairman of ResearchPoint Global. “In addition, we are now able to offer clients deep local knowledge and a significant clinical resource base in both Spain and Portugal.”

Among the attractions of Spain as a location for clinical trials, RPG cited the high number of “world-renowned” investigators and proven investigational sites, universal national health coverage, a well-organised regulatory process and the availability of experienced clinical research associates and project managers.

Spain is also “considered a major hub for the implementation of trials in certain therapeutic areas, such as oncology, acute cardiology, infectious diseases and AIDS”, it noted.

Joining the RPG family will give Pivotal “geographic breadth via the RPG established partnership, while Pivotal will provide the therapeutic depth, a specialised medical hub and a well established DMBS group”, said Dr Ibrahim Farr, the Spanish company’s founder, chairman and chief executive officer.

With several years of double-digit growth under its belt, Pivotal is now “a reference CRO in our region”, he added. In addition to its strong presence in Spain, the company has successfully implemented and managed trials across western European countries such as Portugal, Italy, France and the UK, Dr Farr pointed out.

RPG already runs 24 regional offices, with coverage in a total of 65 countries. The alliance with Pivotal will complement the US CRO’s existing presence in the Americas, Africa, Europe (Western, Central, and Eastern) and India.